SCHEMBL21225322

SCHEMBL21225322

C[C@H]1CNC[C@@H]1NC(=O)c1cc2cc(Cl)c(F)c(F)c2[nH]1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 8/20 0.39
▸ SYK P43405 3/20 0.37
▸ PYGM P11217 2/20 0.37
▸ TAS1R3 Q7RTX0 2/20 0.35
▸ TAS1R1 Q7RTX1 2/20 0.35
▸ TAS1R2 Q8TE23 2/20 0.35
▸ HRH4 Q9H3N8 3/20 0.35
▸ DRD4 P21917 1/20 0.34
▸ MLLT1 Q03111 1/20 0.33
▸ SMYD3 Q9H7B4 1/20 0.33
▸ EHMT2 Q96KQ7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21225314 1.00 PYGL (0.39) PYGLSYKPYGMTAS1R3TAS1R1
SCHEMBL21225298 1.00 PYGL (0.39) PYGLSYKPYGMTAS1R3TAS1R1
SCHEMBL21225563 1.00 PYGL (0.39) PYGLSYKPYGMTAS1R3TAS1R1
SCHEMBL21225574 0.90 TAS1R3 (0.38) PYGLSYKPYGMTAS1R3TAS1R1
SCHEMBL21235175 0.87 PYGL (0.40) PYGLSYKPYGMHRH4MLLT1
SCHEMBL21225190 0.87 PYGL (0.40) PYGLSYKPYGMHRH4MLLT1
SCHEMBL21225430 0.87 PYGL (0.40) PYGLSYKPYGMHRH4MLLT1
SCHEMBL21225590 0.87 PYGL (0.40) PYGLSYKPYGMHRH4MLLT1
SCHEMBL21225349 0.87 PYGL (0.40) PYGLSYKPYGMHRH4MLLT1
SCHEMBL23002856 0.86 PYGL (0.39) PYGLSYKPYGMHRH4MLLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018033-B2 Inhibitors of protein arginine deiminases FORWARD THERAPEUTICS, INC. (US) 2024-06-25 — — US claimed
US-11453676-B2 Inhibitors of protein arginine deiminases FORWARD THERAPEUTICS, INC. (US) 2022-09-27 — — US claimed
US-20210053975-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2021-02-25 — — US claimed
EP-3746430-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES Padforward LLC (US) 2020-12-09 — — EP claimed
WO-2019152883-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES PADFORWARD LLC (US) 2019-08-08 — — WO claimed
US-12018033-B2 Inhibitors of protein arginine deiminases FORWARD THERAPEUTICS, INC. (US) 2024-06-25 — — US disclosed
US-20230151018-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230151018-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-11453676-B2 Inhibitors of protein arginine deiminases FORWARD THERAPEUTICS, INC. (US) 2022-09-27 — — US disclosed
US-20210053975-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2021-02-25 — — US disclosed
US-20210053975-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES FORWARD THERAPEUTICS, INC. 2021-02-25 — — US disclosed
WO-2019152883-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES PADFORWARD LLC (US) 2019-08-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151018-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES PADI2, PADI1, PADI4 PYGL 113/4885SYK 2709/4885PYGM 201/4885
US-11453676-B2 Inhibitors of protein arginine deiminases PADI2, PADI1, PADI4 PYGL 110/4885SYK 2693/4885PYGM 222/4885
US-20210053975-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES PADI2, PADI1, PADI4 PYGL 113/4885SYK 2709/4885PYGM 201/4885
US-12018033-B2 Inhibitors of protein arginine deiminases PADI2, PADI1, PADI4 PYGL 121/4885SYK 2547/4885PYGM 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback